A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

No strong warning signs right now. The score counts warning signs; it is not a prediction.

Why this score

Score over time

What counts as success

The trial's main goal(s), called the “primary outcome.”

• Part 1: Number Of Participants Experiencing Dose-limiting Toxicities (DLTs)

  Measured over: Up to 28 days

• Part 1 And 2: Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Adverse Events Leading to Discontinuation and Adverse Events of Special Interest (AESIs).

  Measured over: Up to 30 days after last dose of study drug

• Part 2: Overall response rate (ORR) as Assessed by Investigator

  Measured over: Approximately 4 years

• Part 2: Very Good Partial Response (VGPR) or Better Response Rate as Assessed by Investigator

  Measured over: Upon study termination (Baseline up to first documentation of disease progression [PD] or death from any cause [approximately 4 years]

• Part 2: Complete Response (CR) or Stringent Complete Response (sCR) as Assessed by Investigator

  Measured over: Upon study termination (Baseline up to first documentation of disease progression [PD] or death from any cause [approximately 4 years])

Changes Tremor has spotted